Meanwhile, SGLT-2 inhibitor studies, including EMPA-REG OUTCOME (n ≈ 7,028) and the CANVAS Program (n ≈ 10,000), consistently reduced heart failure hospitalization and cardiovascular mortality, reinforcing their clinical impact. The gene discussed is SLC5A2; the disease is heart failure.